Pfizer (NYSE:PFE) and its partner BioNTech (NSDQ:BNTX) continue to dominate the COVID-19 vaccine market.
In 2021, Pfizer anticipates that the Comirnaty (BNT162b2) vaccine will generate $36 billion in sales.
For the sake of comparison, the company’s overall 2020 revenue was $41.9 billion.
The vaccine was the single biggest driver of revenue for the company in the third quarter, which totaled $24.1 billion overall. Compared to the same quarter last year, revenues increased 130%. Excluding Comirnaty sales, revenues grew 7% year over year.
Earlier this year, Pfizer projected that sales of the vaccine would be in the ballpark of $33.5 billion.Pfizer CEO Dr. Albert Bourla stressed that the global nature of its COVID-19 vaccine sales growth. “For example, more than 75% of the revenues we have recorded up through thir…